Advocacy and Development Support – Legislation and Policy Focused
Our unmatched expertise in legislative and policy advocacy, coupled with a deep understanding of incentives like Regulatory Data Protection and Market Exclusivity, uniquely positions us to empower global pharmaceutical companies and EU policymakers. We excel in mastering complex legislative terrains, meticulously evaluating the impact of regulatory changes on company pipeline risks and broader healthcare systems. Recognised as thought leaders in portfolio exposure analysis, we provide strategic insights into development decisions and advocacy efforts. Our approach is crafted to address unmet needs and to capitalise on opportunities in an environment marked by increased uncertainty and risk. This focus ensures our clients are not only managing the changes in risk from evolving regulations, but also leveraging these changes to their competitive advantage.
Market Access and Commercial Support – Product Focused
Our market access and commercial support services excel in bridging the gap between policy research and market realities. Tailored for early-stage products, we facilitate seamless transitions from policy to commercial success, especially for access executives in global pharma companies. We specialise in bringing innovative treatments to patients, focusing on market access and launch strategies for global and local levels of international companies. Through executing peer reviewed, real-world evidence studies and conducting budget-impact assessments, we align our strategies with the needs of global pharma companies and local healthcare authorities alike. Our approach encompasses healthcare savings, socioeconomic advantages, and quality of life enhancements. This holistic view allows for a more accurate assessment of the true cost and value proposition of introducing new treatments into the healthcare landscape. Our innovative pricing tool based on applied game-theory is instrumental in maximising the market potential of new treatments, ensuring financial viability and maximum patient access.
